Development and validation of a laboratory-developed test on Panther Fusion(R) system for detection of macrolide resistance in Bordetella pertussis
- 1Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute
Abstract
Macrolides remain the first-line antimicrobial treatment for pertussis, primarily caused by Bordetella pertussis. Emergence of macrolide-resistant B. pertussis in Australia and globally presents a growing concern for clinical management. As molecular diagnosis predominates for pertussis, limited numbers of cultures are available for antimicrobial susceptibility testing. The A2037G mutation in the 23S rRNA gene is most commonly associated with macrolide resistance in B. pertussis, yet no commercial molecular assay is available for its detection. In this study, we adapted and validated a previously published real-time PCR assay as a laboratory developed test (LDT) on the Panther Fusion(R) system using Open Access-functionality to detect the macrolide resistance-associated mutation in B. pertussis from culture isolates and clinical specimens. Total turnaround time was [~]2.5 h for the first result and 2-3 min for subsequent results in the same batch, with an estimated cost of AUD 18 per sample, excluding labour. A total of 30 samples were included in the validation panel to assess assay performance. All isolates and clinical specimens in the validation panel produced results concordant with the expected mutation status, demonstrating 100% accuracy, sensitivity and specificity. The assay demonstrated a limit of detection of 1.5 x 103 CFU/mL (22 CFU/reaction). This Panther Fusion(R) LDT provides a rapid and fully automated approach for molecular detection of the targeted mutation associated with macrolide resistance in B. pertussis. Its integration into routine molecular workflows as a reflex test following identification of B. pertussis may facilitate timely identification of resistant infections.
Related
- Development and validation of a nomogram-based predictive model for infectious diseases of the spine utilizing peripheral blood laboratory parameters
- Baseline and Dynamic Clinical-Laboratory Risk Models for Early Progression or Death During PD-(L)1 Blockade in Advanced NSCLC: Development and Internal Validation.
- Interpretable prediction model for severe community-acquired pneumonia in adults: machine learning development and validation using routine laboratory parameters
- A Laboratory-Based Triage Model for Hepatocellular Carcinoma Early-Detection Pathways in Hospital-Evaluated Populations: Development and External Validation.
- Integrating Anti-SARS-CoV-2 Spike Protein IgG, IL-6, and NK Cell Percentage with Routine Laboratory Markers for COVID-19 Severity Assessment: Development and Validation of the CORIS Nomogram.
BibTeX
@misc{kumar2026development,
title = {{Development and validation of a laboratory-developed test on Panther Fusion(R) system for detection of macrolide resistance in Bordetella pertussis}},
author = {L. Sadeesh Kumar and M. Sait and B. P. Howden and N. L. Sherry},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.22.26363724},
url = {https://www.medrxiv.org/content/10.64898/2026.09.22.26363724v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Development and validation of a laboratory-developed test on Panther Fusion(R) system for detection of macrolide resistance in Bordetella pertussis
AU - L. Sadeesh Kumar
AU - M. Sait
AU - B. P. Howden
AU - N. L. Sherry
PY - 2026
DA - 2026/09/22
PB - medRxiv
DO - 10.64898/2026.09.22.26363724
UR - https://www.medrxiv.org/content/10.64898/2026.09.22.26363724v1
AB - Macrolides remain the first-line antimicrobial treatment for pertussis, primarily caused by Bordetella pertussis. Emergence of macrolide-resistant B. pertussis in Australia and globally presents a growing concern for clinical management. As molecular diagnosis predominates for pertussis, limited numbers of cultures are available for antimicrobial susceptibility testing. The A2037G mutation in the 23S rRNA gene is most commonly associated with macrolide resistance in B. pertussis, yet no commercial molecular assay is available for its detection. In this study, we adapted and validated a previously published real-time PCR assay as a laboratory developed test (LDT) on the Panther Fusion(R) system using Open Access-functionality to detect the macrolide resistance-associated mutation in B. pertussis from culture isolates and clinical specimens. Total turnaround time was [~]2.5 h for the first result and 2-3 min for subsequent results in the same batch, with an estimated cost of AUD 18 per sample, excluding labour. A total of 30 samples were included in the validation panel to assess assay performance. All isolates and clinical specimens in the validation panel produced results concordant with the expected mutation status, demonstrating 100% accuracy, sensitivity and specificity. The assay demonstrated a limit of detection of 1.5 x 103 CFU/mL (22 CFU/reaction). This Panther Fusion(R) LDT provides a rapid and fully automated approach for molecular detection of the targeted mutation associated with macrolide resistance in B. pertussis. Its integration into routine molecular workflows as a reflex test following identification of B. pertussis may facilitate timely identification of resistant infections.
ER -